Rohan Prasad
Lansing, MINPI 1356966337
Payments from drug & device makers
What this record shows
Abbott accounts for 60.6% of it on its own, with 28 other manufacturers making up the rest.
Across 178 payments — averaging $72.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$8K
- Amgen$659
- AstraZeneca$641
- Boston Scientific$584
- Pfizer$541
- Boehringer Ingelheim$341
- plus $2K from 23 others
What the payments were for
- Grants$7,65059%
- Food & beverage$5,27041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $7,825 |
| Amgen | 26 | $659 |
| AstraZeneca | 18 | $641 |
| Boston Scientific | 12 | $584 |
| Pfizer | 26 | $541 |
| Boehringer Ingelheim | 17 | $341 |
| E.r. Squibb & Sons, L.L.C. | 12 | $211 |
| Abiomed | 3 | $201 |
| Medtronic | 5 | $191 |
| Philips North America LLC | 2 | $182 |
| Novartis | 9 | $181 |
| Actelion Pharmaceuticals US, Inc. | 5 | $157 |
| Alnylam Pharmaceuticals Inc. | 5 | $151 |
| Johnson & Johnson | 6 | $142 |
| Lilly USA, LLC | 1 | $120 |
| Edwards Lifesciences | 2 | $116 |
| Gilead | 1 | $113 |
| Bayer | 6 | $103 |
| Axsome Therapeutics, Inc. | 1 | $101 |
| Shockwave Medical, Inc | 1 | $80 |
| Lexicon Pharmaceuticals, Inc. | 3 | $71 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $45 |
| Bridgebio Pharma, Inc. | 2 | $44 |
| United Therapeutics Corporation | 1 | $26 |
| Terumo Medical Corporation | 1 | $26 |
| AbbVie | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$1,575
- ASSURITY$1,575
- TACTICATH$1,000
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$151
- Repatha$120
- ZEPBOUND$120
- Impella$116
- Veklury$113
- (6571) Eagle Eye$108
- BRILINTA$102
- Auvelity$101
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $13,439 |
| Prasugrel Hcl | 13 | $908 |
| Metoprolol Succinate | 34 | $537 |
| Atorvastatin Calcium | 35 | $494 |
| Rosuvastatin Calcium | 20 | $456 |
| ClopidogrelClopidogrel Bisulfate | 20 | $390 |
| Carvedilol | 15 | $349 |
| Losartan Potassium | 20 | $219 |
| Amlodipine Besylate | 15 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $541 | $13,43913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Michiganon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.